UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

[X]  QUARTERLY  REPORT  PURSUANT  TO SECTION 13 OR 15(d) OF THE  SECURITIES
     EXCHANGE ACT OF 1934

                 For the Quarterly Period Ended: March 26, 2005

                                       or

[ ]  TRANSITION  REPORT  PURSUANT  TO SECTION 13 OR 15 (d) OF THE  SECURITIES
     EXCHANGE ACT OF 1934

For the Transition Period from       to            
                               -----    -----------

Commission File Number:    1-11064


                                BRITESMILE, INC. 
             (Exact name of registrant as specified in its charter)

                 UTAH                                     87-0410364
---------------------------------------------  --------------------------------
(State or other jurisdiction of incorporation  (IRS employer identification no.)
            or organization)

                 490 North Wiget Lane
               Walnut Creek, California                     94598
-------------------------------------------        ---------------------------
 (Address of principal executive offices)               (Zip Code)


                                 (925) 941-6260
                (Issuer's telephone number, including area code)


              (Former name, former address and former fiscal year,
                         if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

Yes      X        No       __
         -

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 12b-2 of the Exchange Act)

Yes      __       No       X
                           -

The Company had 10,602,677 shares of common stock outstanding at April 15, 2005.








                        BRITESMILE, INC. AND SUBSIDIARIES


                                TABLE OF CONTENTS





PART I.   FINANCIAL INFORMATION


Item 1.   Financial Statements (Unaudited)

                                                                                                      
         Condensed Consolidated Balance Sheets as of March 26, 2005 and December 25, 2004.................3

         Condensed Consolidated Statements of Operations for the 13 weeks ended
         March 26, 2005 and March 27, 2004................................................................4

         Condensed Consolidated Statements of Cash Flows for the 13 weeks ended
         March 26, 2005 and March 27, 2004................................................................5

         Notes to Condensed Consolidated Financial Statements.............................................6

Item 2.   Management's Discussion and Analysis of Financial Condition and Results of Operations...........11

Item 3.   Quantitative and Qualitative Disclosures About Market Risk......................................17

Item 4.   Controls and Procedures.........................................................................17



PART II.   OTHER INFORMATION


Item 1.  Legal Proceedings................................................................................18

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds......................................20

Item 3.  Defaults upon Senior Securities..................................................................21

Item 4.   Submission of Matters to a Vote of Security Holders.............................................21

Item 5.  Other Information................................................................................21

Item 6.  Exhibits.........................................................................................21







                                       2







                         PART I - FINANCIAL INFORMATION

ITEM 1...FINANCIAL STATEMENTS

                                BRITESMILE, INC.
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (unaudited)
                       ($ in thousands, except share data)


                                                                                      March 26, 2005     December 25,
                                                                                                             2004
                                                                                     ---------------     --------------
ASSETS
CURRENT ASSETS:
                                                                                                             
    Cash and cash equivalents........................................                $      13,948       $      18,880
    Trade accounts receivable, net of allowances of $469 and $448....                        1,986               2,118
    Inventories......................................................                        1,130               1,635
    Prepaid expenses and other.......................................                        1,003                 704
                                                                                     ---------------     --------------
                Total current assets.................................                       18,067              23,337
                                                                                     ---------------     --------------

PROPERTY AND EQUIPMENT, NET..........................................                       12,252              12,426
OTHER ASSETS.........................................................                        3,325               3,843
INTANGIBLES, NET.....................................................                        5,305               5,469
                                                                                     ---------------     --------------

TOTAL ASSETS.........................................................                $      38,949       $      45,075
                                                                                     ===============     ==============

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
    Accounts payable.................................................                $         4,817     $         5,182
    Accrued liabilities .............................................                          4,874               5,394
    Gift certificates and prepaid appointments.......................                            739               1,318
    Deferred revenue ................................................                          1,857               1,049
    Accrual for Center closures......................................                            184                 155
    Long-term debt - current portion.................................                          1,000                 100
    Convertible debt - current portion...............................                             23                 432
    Capital lease obligations with related parties - current portion.                            831               1,605
                                                                                     ---------------     --------------
              Total current liabilities..............................                         14,325              15,235
                                                                                     ---------------     --------------

LONG TERM LIABILITIES:
    Capital lease obligations with related parties - less current portion                         97                 225
    Accrual for Center closures......................................                            510                 596
    Long-term debt - less current portion.............................                         4,765               5,698
    Convertible debt - less current portion...........................                         5,694               5,125
    Financial instruments related to convertible debt.................                         1,069               4,602
    Other long-term liabilities......................................                          1,117               1,012
                                                                                     ---------------     --------------
                    Total long-term liabilities......................                         13,252              17,258
                                                                                     ---------------     --------------
              Total liabilities......................................                         27,577              32,493
                                                                                     ---------------     --------------

SHAREHOLDERS' EQUITY:
    Common stock, $.001 par value; 50,000,000 shares authorized;
    10,522,646 and 10,345,974 shares issued and outstanding, respectively                         38                  38
    Additional paid-in capital.......................................                        172,581             170,601
    Accumulated deficit..............................................                       (161,247)           (158,057)
                                                                                     ---------------     --------------
              Total shareholders' equity ............................                         11,372              12,582
                                                                                     ---------------     --------------

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY...........................                $        38,949     $        45,075
                                                                                     ===============     ==============


                  See notes to condensed consolidated financial
                                  statements.
                                       3



                                BRITESMILE, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)
                       ($ in thousands, except share data)




                                                                          13 Weeks Ended           13 Weeks Ended
                                                                          March 26, 2005           March 27, 2004
                                                                       ---------------------    ---------------------
REVENUES:
                                                                                                       
    Center whitening fees, net...................................      $          4,432         $          4,341
    Associated Center whitening fees, net........................                 4,162                    5,007
    Product sales and other revenue..............................                 1,353                    2,422
                                                                       ---------------------    ---------------------

       Total revenues, net.......................................                 9,947                   11,770
                                                                       ---------------------    ---------------------

OPERATING COSTS AND EXPENSES:
    Operating and occupancy costs................................                 4,201                    4,106
    Selling, general and administrative expenses.................                 9,059                    6,842
    Research and development expenses............................                    75                      172
    Depreciation and amortization................................                 1,591                    1,673
                                                                       ---------------------    ---------------------

       Total operating costs and expenses........................                14,926                   12,793
                                                                       ---------------------    ---------------------

          Loss from operations...................................                (4,979)                  (1,023)
                                                                       ---------------------    ---------------------

OTHER INCOME AND EXPENSES:
    Gain on mark-to-market of financial instruments related to
    convertible debt                                                              2,730                        -
    Amortization of discount on debt                                               (637)                       -
    Interest and Other Expense, net..............................                  (208)                    (162)
                                                                       ---------------------    ---------------------

          Loss before income tax provision.......................                (3,094)                  (1,185)

INCOME TAX.......................................................                    96                       57
                                                                       ---------------------    ---------------------

          Net loss ..............................................      $         (3,190)        $         (1,242)
                                                                       =================        =================

BASIC AND DILUTED NET LOSS PER SHARE.............................      $          (0.30)        $          (0.12)
                                                                       ==================       =================

WEIGHTED AVERAGE SHARES - BASIC AND DILUTED......................
                                                                             10,491,815               10,192,292
                                                                         ==============           ==============











                  See notes to condensed consolidated financial
                                  statements.

                                       4



                                BRITESMILE, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                    Unaudited
                       ($ in thousands, except share data)



                                                                                      13 Weeks Ended             13 Weeks Ended
                                                                                      March 26, 2005             March 27, 2004
                                                                                  -----------------------    -----------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
                                                                                                                     
   Net loss............................................................           $         (3,190)          $         (1,242)
   Adjustments to reconcile net loss to net cash used in operating activities:
         Depreciation and amortization ...............................                       1,599                      1,928
         Amortization of discount of debt                                                      637                          -
         Gain on mark-to-market of financial instruments related to convertible
             debt.....................................................                      (2,730)                         -
         Non-cash compensation expense for restricted stock                     
                                                                                               693                          -
         Increase in variable deferred payments to a related party....                           -                        514
         Other........................................................                           9                         63
   Change in assets and liabilities, net...............................                        (66)                    (2,838)
                                                                                  -----------------------    -----------------------

                  Net cash used in operating activities................                     (3,048)                    (1,575)
                                                                                  -----------------------    -----------------------

CASH FLOWS FROM INVESTING ACTIVITIES
  Purchase of property and equipment...................................                       (958)                      (465)

CASH FLOWS FROM FINANCING ACTIVITIES:
  Payments on capital lease ............................................                    (1,001)                       (61)
  Payments on debt .....................................................                         -                     (2,269)
  Proceeds from common stock offerings, net.............................                         -                      6,340
  Proceeds from exercise of stock options ..............................                        75                        117
                                                                                  -----------------------    -----------------------

                  Net cash provided by (used in) financing activities..                       (926)                     4,127
                                                                                  -----------------------    -----------------------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                        (4,932)                     2,087

CASH AND CASH EQUIVALENTS AT BEGINNING
    OF THE PERIOD                                                                           18,880                      5,884
                                                                                  -----------------------    -----------------------

CASH AND CASH EQUIVALENTS AT END OF THE PERIOD                                    $         13,948           $          7,971
                                                                                  =======================    =======================












                  See notes to condensed consolidated financial
                                  statements.

                                       5



                        BRITESMILE, INC. AND SUBSIDIARIES

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)
                                 March 26, 2005

1.       Description of Business and Basis of Presentation

BriteSmile, Inc., a Utah corporation ("BriteSmile" or the "Company"), and its
affiliates develop, distribute, market, sell and lease advanced teeth whitening
technology, products, systems and services. Unless specified to the contrary
herein, references to BriteSmile or to the Company refer to the Company and its
subsidiaries on a consolidated basis. The Company's operations include the
development of technologically advanced teeth whitening processes that are
distributed in professional salon settings known as BriteSmile Professional
Teeth Whitening Centers ("Centers"). The Company also offers its products and
technologies through arrangements with existing independent dental offices known
as BriteSmile Professional Teeth Whitening Associated Centers ("Associated
Centers"). As of March 26, 2005, the Company had 15 Centers and 5,107 Associated
Centers in operation.

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial information and with the
instructions in Form 10-Q and Article 10 of Regulations S-X. Accordingly, they
do not include all of the information and footnotes required by accounting
principles generally accepted in the United States for annual financial
statements. In the opinion of management, all adjustments (consisting of normal
recurring accruals) considered necessary for a fair presentation have been
included. Operating results for the 13 weeks ended March 26, 2005 are not
necessarily indicative of the results that may be expected for the remainder of
the fiscal year ending December 31, 2005.

2.       Stock Based Compensation

The Company uses the intrinsic value method to account for its stock based
compensation plans. The alternative fair value accounting of the Company's
options for the first quarter of 2005 was estimated at the date of grant using a
Black-Scholes option pricing valuation model with the following weighted-average
assumptions: volatility of 0.65; a risk-free interest rate of 4.30% for the 13
week period ended March 26, 2005; dividend yield of 0%; and a weighted-average
expected life of the option of 4.66 years for the 13 week period ended March 26,
2005. Had compensation cost for the Company's stock-based compensation plans
been determined using the Black-Scholes option pricing valuation model, the
Company's reported net loss applicable to common shareholders and basic and
diluted net loss per share would have been increased to the pro forma amounts
indicated below (in thousands, except per share data):



                                                                          13 Weeks Ended      13 Weeks Ended
                                                                          March 26, 2005      March 27, 2004
                                                                         ------------------ -------------------

                                                                                                     
        Loss as reported...................                              $         (3,190)  $          (1,242)
        Compensation expense reported under APB25                                        -                   -
        Compensation expense computed using fair value method                          582                 715
                                                                         ------------------ -------------------
        Pro forma loss.....................                              $         (3,772)  $          (1,957)
                                                                         ================== ===================
        Pro forma basic and diluted loss per share
                                                                         $          (0.36)  $           (0.19)
                                                                         ================== ===================


240,000 shares of restricted stock were granted to the new Chief Executive
Officer upon his hire date of January 9, 2005. The value of $1.5 million will be
expensed over two years. The Chief Executive Officer was also granted an option
for the purchase of 600,000 shares of common stock at $6.30 per share.

                                       6




                        BRITESMILE, INC. AND SUBSIDIARIES

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)
                                 March 26, 2005

For further information, refer to the consolidated financial statements and
footnotes thereto included in the Company's Annual Report on Form 10-K for the
52 weeks ended December 25, 2004.

3.       Loss Per Common Share

Basic net loss per share is calculated as net loss divided by the
weighted-average number of common shares outstanding. Diluted net loss per share
is equal to basic net loss as the Company has recorded a net loss. Stock options
totaling 1,922,702 shares and warrants totaling 1,189,963 shares and convertible
notes payable have been excluded from the calculation of net loss per share for
the 13 week period ended March 26, 2005 as their effect is anti-dilutive. Stock
options totaling 852,230 shares and warrants totaling 332,825 shares and
convertible notes payable have been excluded from the calculation of net loss
per share for the 13 week period ended March 27, 2004 as their effect is
anti-dilutive.

4.       Debt

The Company has certain financial  instruments  related to its convertible debt.
The estimated fair value amounts have been determined using  appropriate  market
information and valuation methodologies. In the measurement of the fair value of
these instruments, the Black-Scholes option pricing model was utilized, which is
consistent with the Company's historical valuation techniques.  The value of the
Financial  Instruments  Related to Convertible  Debt - Warrants was treated as a
liability  and  marked-to-market  based  on the  current  stock  price  with the
resulting  gain or loss  reflected  in the income  statement.  As of February 4,
2005, the Company  registration  statement relating to the warrants was declared
effective  which  triggered the financial  instrument to convert to equity.  The
value of the Financial  Instruments Related to Convertible Debt - Warrants as of
the date of conversion was $1.2 million.  As of the quarter end, March 26, 2005,
the value of the Financial  Instruments Related to Convertible Debt - Additional
Investment Rights was $23,000 and the value of the Financial Instruments Related
to Convertible Debt - Conversion  Feature was $1.1 million.  The  mark-to-market
gain on Financial  Instruments  Related to Convertible Debt in the first quarter
of 2005 was $2.7 million.

In February 2005, the Company paid $1.0 million due under the amended capital
lease agreement with EVL for the variable rent portion of the monthly payment
due beginning November 2003 through December 2004 and the fixed rent portion of
the monthly payment due beginning January 2004 through December 2004, with
interest payable on the deferred amount at a rate equal to LIBOR, plus 250 basis
points. Under the amended capital lease agreement another $1.0 million of
deferred rent is due February 15, 2006, and the remaining balance is due to be
paid on February 15, 2007. As of March 26, 2005, the unpaid variable rent was
$2.5 million, of which $1.4 million is included in long-term debt. As of March
26, 2005, the unpaid fixed rent was $928,000 of which $831,000 is current.

5.       Legal Proceedings

The Company is the subject of certain legal actions. Management does not believe
that current pending litigation involving the Company will have a material
adverse effect on the Company's consolidated financial position or results of
operations. This conclusion has been developed in consultation with outside
counsel handling BriteSmile's defense in the matters. However, the litigation
and other claims noted in this report are subject to inherent uncertainties and
it is possible that future results of operations for any particular quarterly or
annual period could be materially affected by changes in management's
assumptions and the effectiveness of BriteSmile's strategies related to these
legal actions.

BriteSmile, Inc. v. Discus Dental, Inc. and Salim Nathoo, filed in the United
States District Court for the Northern District of California (the "Discus
Patent Litigation"). The Company filed an initial complaint against Discus
Dental, Inc. ("Discus"), Culver City, California, in July 2002. As amended to
date, the complaint asserts claims of infringement of the Company's U.S. Patents
Nos. 6,343,933, 6,514,543 and 6,536,628. In February 2003, the Company amended
the Discus Patent Litigation by adding Salim Nathoo ("Nathoo") as a defendant.
The complaint, as amended, further alleges misappropriation of the Company's
trade secrets, civil conspiracy, and unfair competition and business practices
by Discus and Nathoo; breach of contract and breach of fiduciary duty by Mr.
Nathoo, and tortuous interference with contract by Discus. The complaint alleges
that Nathoo and Discus conspired to misappropriate BriteSmile's trade secrets in

                                       7


violation of Nathoo's contractual obligations to the Company. The amended
lawsuit alleges that, as BriteSmile's Medical Director, Nathoo had, and
continues to have, an obligation to keep BriteSmile's trade secrets
confidential. Beginning in 2001, Discus Dental and Nathoo entered into an
agreement whereby Discus Dental paid Nathoo at least $2.5 million over a less
than two year period for Nathoo's "consulting" services, which included paying
Nathoo to share with Discus certain of the Company's trade secrets. The lawsuit
alleges further that in December 2002, a third party informed BriteSmile of
Nathoo's activities, and that when confronted by BriteSmile, Nathoo admitted to
receiving $2.5 million from Discus. The Company seeks a permanent injunction
against both Discus and Nathoo to prevent further infringement of its patents
and improper disclosure of the Company's trade secrets, lost profits, treble
damages and attorneys fees for willful patent infringement, punitive damages,
and other relief.

In March 2003, Discus filed its answer to the amended complaint and
counterclaims. In its answer, Discus denies any liability for BriteSmile's
claims. Discus also raises affirmative defenses, including claims that its
products and processes do not infringe BriteSmile's patents and that
BriteSmile's patents are invalid and unenforceable. Discus asserts counterclaims
against BriteSmile, seeking (i) judicial declarations that BriteSmile's patents
are invalid, unenforceable, and have not been infringed, (ii) tortuous
interference with prospective economic advantage and economic business
relations, and (iii) unfair competition. Discus also asks for declarations that
its products and processes do not violate BriteSmile's patents, that
BriteSmile's patents are unenforceable, that BriteSmile has no protectable trade
secrets, and that BriteSmile's contracts with Associated Center dentists which
contain contractual restrictions on the purchase and use of competitive systems
are unenforceable and should be enjoined, and is seeking lost profits, treble
damages and attorneys fees.

In July 2003, the case of Salim Nathoo v. BriteSmile Leasing (discussed below)
was consolidated with the Discus Patent Litigation.

In April 2004, Nathoo filed an answer and counterclaim to the Company's
complaint, as well as a third party complaint against Montgomery, who is a
director of the Company, and several of Montgomery's companies, alleging breach
of contract, breach of covenant of good faith and fair dealing, trade secret
misappropriation, patent infringement, and civil conspiracy. In August 2004,
Nathoo filed an amended answer and counterclaims to the Company's complaint. In
his new amended counterclaims, Nathoo brought claims for correction of
inventorship of several of the Company's patents; infringement by the Company of
those same patents; misappropriation of trade secrets by the Company, Montgomery
and several of his companies, and the following Company employees or directors:
John Reed, John Warner and Anthony Pilaro; conversion by the Company, Montgomery
and his companies, Reed, Warner and Pilaro; constructive trust for the patents
he claims have incorrect inventorship; fraud against the Company, Montgomery,
Reed, Warner and Pilaro; breach of contract by the Company, Montgomery, Reed,
Warner, Pilaro and CAP Advisors Limited; tortious interference with contract by
the Company; a declaration that the Company has no protectable trade secrets;
and unfair competition against the Company, Montgomery and his companies, Reed,
Warner and Pilaro. In October 2004, Nathoo filed another amended answer and
counterclaims in which he dropped his allegations of patent infringement.

In May 2005, the Court dismissed with prejudice seven of Nathoo's counterclaims
pertaining to correction of inventorship as well as the counterclaim against CAP
Advisors for breach of contract.  The Court issued the claims construction order
construing the five claims in dispute in May 2005, and the parties have been
asked to submit a case schedule.  Further written discovery, document
production and depositions will continue.

BriteSmile v. Discus Dental, Inc., filed in Contra Costa County Superior Court,
California. In May 2002, the Company filed a complaint against Discus Dental,
Inc. in Contra Costa County Superior Court, California, alleging causes of
action for intentional interference with contractual relationship, negligent
interference with contractual relationship, violation of Unfair Business
Practice Act - Loss Leader, violation of Unfair Business Practice Act, trade
libel and injunctive relief. The complaint alleges that Discus Dental and other
defendants yet to be identified wrongfully interfered with the Company's
contractual relationships with its Associated Center Dentists, in part by
writing letters with the purpose of inducing certain of the Company's Associated
Dentists to terminate their contracts with the Company and switch to Discus'
Zoom! system, and by making false and disparaging statements concerning the
Company's teeth whitening system. The Complaint seeks damages for loss of
business, punitive damages, injunctive relief, and costs of suit. This case was
stayed in March 2003 pending the resolution of the Discus Patent Litigation.

                                       8


Smile Inc. Asia Pte. Ltd. v. BriteSmile In April 2002, Smile Inc. Asia Pte. Ltd.
("Smile") sued the Company and BriteSmile Management, Inc., a wholly owned
subsidiary of the Company ("BriteSmile Management"), in the Third Judicial
District Court in Salt Lake City, Utah. The complaint alleges that BriteSmile
Management breached its 1998 distributor agreement with Smile (exclusive as to
Singapore and other surrounding countries) by failing to fill orders placed and
to perform other obligations under the agreement. The complaint also alleges
that BriteSmile Management and the Company fraudulently induced Smile to enter
into the distributor agreement, and includes claims for damages based on alleged
unjust enrichment, civil conspiracy, breach of the duty of good faith and fair
dealing, interference with contractual and economic relations, and fraudulent
transfer.

In May 2002, the Company and BriteSmile Management filed their answer and
counterclaim. The counterclaim alleges that Smile breached the distributor
agreement by, among other things, failing to operate using a licensed dentist in
good standing (the license of the principal of Smile, Dr. Tan, was not
maintained in good standing during 1999) and using BriteSmile's names and marks
in a fashion not permitted by the distributor agreement.

One of the principal defenses to Smile's claims is that the distributor
agreement expressly excludes "non-laser-aided teeth whitening products and
processes" sold by the Company. Accordingly, in the lawsuit the Company asserts
the distributorship agreement does not grant Smile any rights to market and sell
the Company's current light activated teeth whitening ("LATW") or retail
products and Smile cannot claim damages for BriteSmile's marketing of such
products in the exclusive territory described in the distributor agreement.

In May 2004, the Company filed a motion to compel Smile to participate in
mandatory binding arbitration and to stay the litigation pending arbitration. In
June 2004, the Court denied the Company's motion to compel arbitration. On July
16, 2004, the Company filed a Notice of Appeal on the issue of compelling this
case to be decided by mandatory binding arbitration. The case is stayed at the
trial level until the appellate court decides whether to compel Smile to
participate in arbitration.

Both parties have produced documents and written responses in support of their
claims and defenses, and depositions of certain key witnesses have been taken
and are continuing. However, the Company is still waiting to receive from Smile
documents and evidence to support Smile's calculation of damages.

While the plaintiff has claimed $10 million in damages, management believes that
the likelihood of material damages to the Company is remote.

Kalow & Springut v. BriteSmile et. al., filed in the Supreme Court of the State
of New York, County of New York. In April 2003, the law firm of Kalow & Springut
("KS") filed a complaint against the Company, BriteSmile International, a
subsidiary of the Company, and Anthony Pilaro, the Company's non-executive
Chairman. KS sought to recover alleged unpaid legal fees and expenses in the
amount of $768,000. Plaintiff also alleged that it was fraudulently induced to
incur the legal fees and expenses and sought to recover punitive damages of at
least $5 million.

On February 14, 2005, the parties settled the case, whereby BriteSmile has
agreed to pay $650,000 to Kalow & Springut in full and final settlement which
had been accrued in prior years.

The Procter & Gamble Company v. Oraceutical LLC, IDEX Dental Sciences, Inc.,
Robert Eric Montgomery, BriteSmile, Inc. and BriteSmile Development, Inc., filed
in the United States District Court for the Southern District of Ohio. In June
2003, The Proctor & Gamble Company ("P&G") filed a complaint against the
defendants listed above alleging that Oraceutical LLC, IDEX Dental Sciences,
Inc. and Robert Eric Montgomery (collectively, the "REM Group") had breached an
agreement between the REM Group and P&G (the "Standstill Agreement") by entering
into a binding memorandum of understanding (the "MOU") with the Company and
BriteSmile Development, Inc. on May 9, 2003. Montgomery is a director of the
Company. Oraceutical LLC, which is owned by Montgomery, is a consultant to the
Company. The complaint also seeks a declaratory judgment that U.S. Patent Nos.
5,922,307, 6,331,292 and 6,488,914 (owned by the REM Group at the time the
complaint was filed) (the "Patents") are invalid and unenforceable, and that
P&G's Whitestrips product does not infringe the Patents. In its complaint P&G
asserts that the REM Group was obligated under the Standstill Agreement not to
take any action that would prevent it from granting rights to P&G under the
Patents sufficient at least for P&G's current Whitestrips products. P&G further

                                       9


alleges that the REM Group breached that obligation by entering into the MOU
and, accordingly, P&G terminated the Standstill Agreement. P&G is seeking
monetary damages of at least $75,000 from the Company under the claims set forth
in its complaint. Defendants have filed a motion to dismiss P&G's declaratory
judgment action for non-infringement and invalidity as well as for breach of the
Standstill Agreement.

In February 2004,  the defendants  filed an answer,  affirmative  defenses,  and
counterclaims.  Affirmative defenses include anticipatory breach, unclean hands,
equitable estoppel, lack of justifiable controversy,  and lack of jurisdictional
amount. The counterclaims  asserted that P&G literally infringed U.S. Patent No.
6,488,914 by among other things,  making,  using, selling or offering to sell in
the United States the Crest Whitestrips.  The counterclaims  further allege that
P&G actively induced  infringement of the patents in suit by providing marketing
assistance  for,  advertising  and  otherwise  promoting  the Crest  Whitestrips
products to others for resale. The claims construction hearing occurred in April
2005 regarding the interpretation of the patent claims, and the ruling from this
hearing is still  pending.  There are currently no new motions  pending with the
Court other than the motion to dismiss filed by the Company at the outset of the
case, and a motion to compel discovery filed by P&G.

The Company is also subject to legal proceedings and claims in the ordinary
course of business, including claims of alleged infringement of trademarks and
other intellectual property rights. The Company is not aware of any such legal
proceedings or claims that it believes will have, individually or in the
aggregate, a material adverse effect on its business, consolidated financial
position, results of operations or liquidity.

6.       Subsequent Events

In April 2005, the Company entered into a Shareholder Agreement with Dental Spa
Company (an unrelated Thailand company) to establish a Thailand company whose
business purpose is to open and operate a new Center in Bankgkok, Thailand. The
Company and Dental Spa Company plan to each contribute $250,000 as initial
capital to fund the Thailand Center and will each have an approximately 50%
economic interest in the center company. This capital investment will be used to
build out the Center, for a down payment on a facility lease, and for general
working capital requirements. The Center, which is not expected to open until
the fourth quarter of 2005, will be located in the Siam Paragon shopping
destination currently under construction.

                                       10




ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

Forward-looking Statements and Risk Factors

The following Management's Discussion and Analysis of Financial Condition and
Results of Operations contains forward-looking statements that involve risks and
uncertainties. Such forward-looking statements may be deemed to include
information that is not historical. The statements contained in this Report that
are not purely historical are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 and Section 21E of the
Securities Exchange Act. These statements relate to the Company's expectations,
hopes, beliefs, anticipations, commitments, intentions and strategies regarding
the future. They may be identified by the use of words or phrases such as
"believes," "expects," "anticipates," "should," "plans," "estimates," and
"potential," among others. Forward-looking statements include, but are not
limited to, statements contained in Management's Discussion and Analysis of
Financial Condition and Results of Operations regarding the Company's financial
performance, revenue and expense levels in the future, and the sufficiency of
its existing assets to fund future operations and capital spending needs. Actual
results could differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. The Company believes
that many of the risks set forth here and in the Company's 10-K Annual Reports
filed with the SEC are part of doing business in the industry in which the
Company operates, and will likely be present in all periods reported. The
forward-looking statements contained in this Report are made as of the date of
this Report and the Company assumes no obligation to update them or to update
the reasons why actual results could differ from those projected in such
forward-looking statements. Among others, risks and uncertainties that may
affect the business, financial condition, performance, development, and results
of operations of the Company include:

     o    Government  regulation of the Company's  products and teeth  whitening
          procedures,  including:  (i) current  restrictions  or controls on the
          practice  of  dentistry  by general  business  corporations,  and (ii)
          future,  unknown enactments or interpretations of current  regulations
          which could, in the future, affect the Company's operational structure
          and relationships with licensed dentists;

     o    Failure  of  the  Company  to  generate,  sustain  or  manage  growth,
          including  failure  to develop  new  products  and  expand  Center and
          Associated Center locations and revenues;

     o    The loss of product market share to competitors  and/or development of
          new or superior technologies by competitors;

     o    Ongoing  operating losses  associated with the development,  marketing
          and   implementation   of   new,   light-activated   teeth   whitening
          technologies;

     o    Failure of the Company to secure  additional  financing to support the
          continued  rollout  of  Centers  and  Associated  Centers  and to meet
          working capital requirements;

     o    Unproven  market for the Company's new whitening  products,  whitening
          process,  and "Whitening Center" and "Associated Center" concepts,  in
          light of competition from traditional take-home whitening products and
          bleaching tray methods;

     o    Failure  to  develop  marketing  strategies  and  delivery  methods to
          penetrate U.S. and non-U.S. markets; and

     o    Lack of product diversity.

The market price of the Company's stock may be inordinately affected by the
Company's financial results which include significant non-cash factors.


                                       11


Critical Accounting Policies And Estimates

General

The Company's discussion and analysis of its financial condition and results of
operations are based upon the Company's consolidated financial statements, which
have been prepared in accordance with accounting principles generally accepted
in the United States of America. The preparation of these financial statements
requires the Company to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses, and related disclosure of
contingent assets and liabilities. On an on-going basis, the Company evaluates
its estimates, including those related to customer programs and incentives, bad
debts, inventories, income taxes, warranty obligations, financing operations,
restructuring, and contingencies and litigation. The Company bases its estimates
on historical experience and on various other assumptions that are believed to
be reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions.

The Company believes the following critical accounting policies affect its more
significant judgments and estimates used in the preparation of its consolidated
financial statements.

Revenue Recognition

BriteSmile recognizes revenue related to retail products at the time such
products are sold to customers.

The Company recognizes revenue from teeth whitening procedures performed at its
Centers when the procedures have been performed. The Company defers the revenue
generated on the sale of key cards and activation codes to Associated Centers
and recognizes the income over the estimated performance period. Discounts to
revenue are recorded at the time the procedure is booked.

BriteSmile's policy is not to accept any return of key cards or access codes
during the course of the agreement with an Associated Center.

In the third quarter of 2004, BriteSmile introduced the Smile Forever program
where Center customers can pay an additional fee for the right to receive an
unlimited number of touch-up procedures over a two-year period. The revenue
associated with this program is deferred and recognized in product sales over
the two-year maintenance period.

Deferred Contract Costs

During 1999, the Company granted warrants to Orthodontic Centers of America
("OCA") in consideration of OCA installing the Company's BS3000 machines in OCA
centers. The value of the warrants was capitalized as deferred contract costs
and is being amortized as a reduction of revenue over the life of the agreement
(10 years).

During 2003, the Company introduced the Magic Mirror, a marketing product
designed to show potential customers what their teeth will look like after an
LATW procedure. The Company provides the Magic Mirror to Associated Centers who
sign a five year contract to purchase a minimum number of key cards each month.
In accordance with EITF 01-09, "Accounting for Consideration Given to a Vendor
by a Customer (Including the Reseller of a Vendor's Products)", the associated
revenue and cost of the Magic Mirrors provided to customers have been
capitalized and are being amortized to revenue and cost of goods sold over the
life of the contract. At March 26, 2005 the amount capitalized was $882,000, net
of deferred revenue received from the sale of Magic Mirrors to customers.

Management will continually assess the recoverability of these costs.

Bad Debt

BriteSmile maintains allowances for doubtful accounts for estimated losses
resulting from the inability of its customers to make required payments. A
considerable amount of judgment is required in assessing the ultimate
realization of accounts receivable including the current credit-worthiness of
each Associated Center. If the financial condition of BriteSmile's customers
were to deteriorate, resulting in an impairment of their ability to make
payments, additional allowances may be required. The allowance for doubtful
accounts at March 26, 2005 was $469,000.

                                       12


Inventory

Inventories are stated at the lower of cost or market. BriteSmile writes down
its inventory for estimated obsolescence or unmarketable inventory equal to the
difference between the cost of inventory and the estimated market value based
upon assumptions about future demand and market conditions, as well as for
damaged goods. If actual market conditions are less favorable than those
projected by management, additional inventory write-downs may be required.

Property, Equipment and Improvements

BriteSmile evaluates its property, equipment and improvements for impairment
whenever indicators of impairment exist. No impairment charge was recorded
during the 13 weeks ended March 26, 2005.

Center Closures

During 2001, BriteSmile recorded significant reserves in connection with Center
closures. These reserves, which were adjusted in 2003, include estimates
pertaining to employee separation costs and the settlements of contractual
obligations, primarily property leases. The Company recorded an additional
reserve in the first quarter of 2004 for severance and lease liabilities
associated with the closure of the Honolulu Center. Although the Company does
not anticipate significant changes, the actual costs related to the closures may
differ from these estimates. In total, the Center closure reserve decreased
$58,000 in the 13 weeks ended March 26, 2005, due to lease payments.

Financial Instruments Related to Convertible Debt

The estimated fair value amounts of the Company's Financial  Instruments Related
to Convertible Debt have been determined using  appropriate  market  information
and  valuation  methodologies.  In the  measurement  of the fair  value of these
instruments,  the Black-Scholes option pricing model was utilized.  The value of
the  Financial  Instruments  Related to  Convertible  Debt - AIR is treated as a
liability  and  marked-to-market  based  on the  current  stock  price  with the
resulting gain or loss reflected in the income  statement until  expiration,  at
which point,  later this year, the liability will be extinguished.  The value of
the Financial  Instruments  Related to Convertible  Debt - Conversion  Option is
treated as a liability  and  marked-to-market  based on the current  stock price
with the resulting gain or loss  reflected in the income  statement for the life
of the debt. As of the quarter end,  March 26, 2005,  the value of the Financial
Instruments  Related to  Convertible  Debt -  Additional  Investment  Rights was
$23,000 and the value of the Financial Instruments Related to Convertible Debt -
Conversion  Feature  was $1.1  million.  The  mark-to-market  gain on  Financial
Instruments  Related to  Convertible  Debt in the first quarter of 2005 was $2.7
million.

Overview

The following discussion should be read in conjunction with the Financial
Statements and the Notes thereto included in Item 1 of this Quarterly Report on
Form 10-Q and in the Company's Annual Report on Form 10-K for the fiscal year
ended December 26, 2004.

Revenue and Deferred Contract Costs:  See Revenue Recognition above.

Operating and occupancy costs are composed primarily of four main groups: 1)
salaries and benefits of Center employees; 2) the operating and occupancy costs
for the Centers including rent; 3) the cost of goods for both the Center and
Associated Center whitening procedure kits and retail products; and 4) the lease
costs for the devices in the Associated Centers.

Selling, general and administrative expenses are composed of all selling and
marketing expenses as well as expenses associated with all corporate and
administrative functions that support existing operations and provide an
infrastructure to support future growth, including management and staff
salaries, employee benefits, travel, professional services, information systems,
operating costs of the Company's call center, training, field support, and
marketing and advertising.

Research and development costs represent expenses related to safety and efficacy
studies as well as other research activities directed at expanding the Company's
position in the teeth-whitening industry.

                                       13


The following table sets forth unaudited operating results for the 13 week
period ended March 26, 2005 as a percentage of sales in the period. This data
has been derived from the unaudited financial statements.



                                                                       13 Weeks         13 Weeks ended
                                                                         ended
                                                                    March 26, 2005      March 27, 2004

                                                                                      
         Revenues:
                  Center whitening fees, net                                 44.6%               36.9%
                  Associated Center whitening fees, net                      41.8%               42.5%
                  Product sales and other revenue                            13.6%               20.6%
                                                                             -----               -----
                  Total revenues, net                                       100.0%              100.0%
                                                                            ------              ------

         Operating Costs and Expenses:
                  Operating and occupancy costs                              42.2%               34.9%
                  Selling, general and administrative expenses               91.1%               58.1%
                  Research and development expenses                           0.8%                1.5%
                  Depreciation and amortization                              16.0%               14.2%
                                                                             -----               -----
                  Total operating costs and expenses                        150.1%              108.7%
                                                                            ------              ------

         Loss from operations                                               -50.1%               -8.7%
                                                                            ------               -----

         Gain on mark-to-market of financial instruments related
         to convertible debt                                                 27.5%                   -
         Interest expense, net and other                                     -8.5%               -1.4%
                                                                             -----               -----

         Loss before income tax provision                                   -31.1%              -10.1%
         Provision for income taxes                                           1.0%                0.5%
                                                                              ----                ----
         Net Loss                                                           -32.1%              -10.6%
                                                                            ======              ======



The following are explanations of significant  period-to-period  changes for the
13 weeks ended March 26, 2005 and March 27, 2004:

Revenues

Total Revenues, net. Total revenues, net decreased by $1.8 million, or 15%, to
$9.9 million for the 13 weeks ended March 26, 2005, from $11.8 million for the
13 weeks ended March 27, 2004.

Center Whitening Fees, net. Center whitening fees increased by $91,000, or 2%,
to $4.4 million for the 13 weeks ended March 26, 2005, from $4.3 million for the
13 weeks ended March 27, 2004. The number of procedures performed in the Centers
increased 5% to 9,253 in the first quarter of 2005, compared to 8,818 in the
same quarter of 2004. Average whitening fees per procedure decreased 3% from
$492 per procedure in the first quarter of 2004 to $479 per procedure in the
first quarter of 2005, as a result of increased discounting. Generally, the
level of discounting varies from period to period based on the market conditions
at the time. The Company is currently reevaluating its forecast of future trends
in fees based on the recent market conditions.

Associated Center Whitening Fees, net. Associated Center whitening fees, net
decreased by $845,000, or 17%, to $4.2 million for the 13 weeks ended March 26,
2005, from $5.0 million for the 13 weeks ended March 27, 2004. The total number
of procedures in all Associated Centers decreased 5% to 29,220 procedures in the
first quarter of 2005 compared to 30,870 procedures in the same quarter of 2004.
Average whitening fees per procedure decreased 7% from $161 per procedure in the
first quarter of 2004 to $149 per procedure for the 13 weeks ended March 26,
2005, primarily due to increased discounting. Generally, the level of
discounting varies from period to period based on the market conditions at the


                                       14


time. The Company is currently reevaluating its forecast of future trends in
fees based on the recent market conditions.

Product Sales and Other Revenue. Product sales decreased by 45% to $1.4 million
for the 13 weeks ended March 26, 2004, from $2.4 million for the 13 weeks ended
March 27, 2004, primarily due to the launch of BriteSmile-to-Go(TM) ("BTG") in
the comparable period in 2004. Domestic retail sales for the first quarter
decreased by approximately $608,000 from the comparable period in 2004.
International retail sales for the first quarter increased by approximately
$4,000. Smile Forever maintenance fees of $101,000 were recognized in the first
quarter of 2005; this maintenance program was not in place in the first quarter
of 2004. Product sales include retail products such as BTG, mouthwash and
toothpaste, sales of Magic Mirrors, recognition of Smile Forever deferred
revenues and payments from customers to reimburse product shipment freight
costs.

Operating Costs and Expenses

Operating and Occupancy Costs. Operating and occupancy costs as a percentage of
net revenues was 42% for the 13 weeks ended March 26, 2005, compared to 35% in
the 13 weeks ended March 27, 2004. This was due to decreased revenue and a
$95,000 increase in occupancy and operating expenses for the quarter, primarily
due to new spas, compared to the same quarter in 2004. The major expense
components in this category are cost of goods sold for all products and
services, operating costs of Centers, which include salaries for the dentist and
supporting staff, lease financing and rent.

Selling, General and Administrative Expenses. Selling, general and
administrative expenses increased as a percentage of net revenues to 91% for the
13 weeks ended March 26, 2005 compared to 58% in the 13 weeks ended March 27,
2004. This was due to reduced sales and significantly increased SG&A expenses
for the quarter compared to the same quarter in 2004. The $2.2 million increase
in selling, general and administrative expenses resulted from new advertising
initiatives expensed during the quarter, increased salaries and benefits
relating to employee terminations and recognition of non-cash compensation of
$693,000 related to the hire in January 2005 of Gregg Coccari as CEO of the
Company. .

Research and Development Expenses. Research and development expenses of $75,000
were 1% of net revenues for the first quarter of 2005 compared to $172,000, or
2%, in the corresponding period in 2004.

Depreciation and Amortization. Depreciation and amortization increased slightly
as a percentage of net sales to 16% for the first quarter of 2005, compared to
14% in the corresponding period in 2004. Depreciation and amortization decreased
on a dollar basis by $82,000 from the corresponding quarter one year ago.

Gain on Mark-to-Market of Financial Instruments Related to Convertible Debt. The
Company has certain financial instruments related to its convertible debt. The
estimated fair value amounts have been determined using appropriate market
information and valuation methodologies. Each financial reporting period the
financial instruments related to convertible debt are revalued using the
mark-to-market approach and gains or losses on the revaluations are recognized
in the current reporting period. The value of the Financial Instruments Related
to Convertible Debt - Warrants was treated as a liability and marked-to-market
based on the current stock price with the resulting gain or loss reflected in
the income statement. As of February 4, 2005, the Company registration statement
relating to the Financial Instruments Related to Convertible Debt - Warrants was
declared effective which triggered the financial instrument to convert to
equity. The value of the Financial Instruments Related to Convertible Debt -
Warrants as of the date of conversion was $1.2 million. As of the quarter end,
March 26, 2005, the value of the Financial Instruments Related to Convertible
Debt - Additional Investment Rights was $23,000 and the value of the Financial
Instruments Related to Convertible Debt - Conversion Feature was $1.1 million.
The mark-to-market gain on Financial Instruments Related to Convertible Debt in
the first quarter of 2005 was $2.7 million.

Amortization of Discount on Debt. The  convertible  debt issued in December 2004
was valued net of discount. That discount is amortized over the life of the debt
using the  effective  interest  method.  For the 13 week period  ended March 26,
2005, the amortization of discount on convertible debt was $570,000, and the
total amortization on debt was $637,000.

Interest  and Other  Expense,  net.  Other  expense,  net  increased  $46,000 to
$208,000,  or 2% of net revenue, for the first quarter of 2005 from $162,000, or
1% of net  revenue,  for the  corresponding  period in 2004.  The  increase  was
primarily  due to  lower  sales in the  quarter  as well as  increased  interest
expense  related to the  Company's  convertible  note issued in  December  2004.
Interest  expense was $305,000;  interest  incomve was $80,000 and other incomve
was $17,000 for the quarter ended March 26, 2005.

Liquidity and Capital Resources

General

The Company's principal sources of liquidity have been proceeds from issuances
of common stock and debt. At March 26, 2005, the Company had $13.9 million in
cash and $0.9 million in borrowing capacity under lines of credit. To date, the
Company has yet to achieve profitability. The Company expects that its principal
uses of cash will be to provide working capital, for debt service, to finance
capital expenditures, and to meet corporate expenses including expanding the
number of Centers and Associated Centers.

The Company made the following changes to its capital resources in 2004:

                                       15


     o    In December  2004,  the Company  obtained $11.2 million (net proceeds)
          from the sale of Convertible  Debt to six investors for the purpose of
          funding new Center expansion and general working capital requirements.

     o    In August 2004,  the Company and Excimer  Vision  Leasing  ("EVL"),  a
          related party, amended BriteSmile's capital lease agreement to provide
          that the total rents deferred under the December 2003 lease  amendment
          would be  deferred  further  such that $1.0  million  would be paid on
          February 15, 2005, $1.0 million would be paid on February 15, 2006 and
          the  remaining  balance due would be paid on February  15,  2007.  The
          first payment was made on February 15, 2005.

     o    In August  2004,  the Company  repaid to EVL the  remaining  principal
          balance of approximately $0.8 million obtained from EVL in March 2001.

     o    In January 2004,  the Company  received $6.8 million from the December
          2003  private  placement  of 923,943  shares of common stock (of which
          $1.7 million was received in December 2003).

The Company believes that cash on hand, together with available borrowing
capacity, will be sufficient to sustain operations for the foreseeable future.
However, we operate in a rapidly evolving and often unpredictable business
environment that may change the timing or amount of expected future cash needs
and cash receipts and expenditures. Accordingly, there can be no assurance that
we will not be required to raise additional funds through the sale of equity or
debt securities or from credit facilities. Additional capital, if needed, may
not be available on satisfactory terms, if at all. Furthermore, additional debt
financing may contain covenants that restrict our operations.

Cash Requirements

During the last three years, the primary uses of cash were for funding of
operations, purchases of property and equipment, and to a lesser degree, debt
repayments. During the first quarter of 2004, the Company repaid a $2 million
bridge loan (including interest) obtained in November 2003 from LCO Investments
Limited ("LCO"), a related party. LCO is the Company's primary shareholder.
During the third quarter of 2004, the Company repaid a loan with a remaining
principal amount of $0.8 million obtained in March 2001 from Excimer Vision
Leasing L.P. ("EVL"), also a related party.

In 2003 and 2004, the Company and EVL amended their capital lease agreement to
provide that the variable rent portion of the monthly payment due beginning
November 2003 and the fixed rent portion of the monthly payment due beginning
January 2004 would be deferred and paid to EVL in annual installments beginning
February 15, 2005, with interest payable on the deferred amount at a rate equal
to LIBOR, plus 250 basis points. As of March 26, 2005, the unpaid variable rent
was $2.5 million, of which $1.4 million is included in long-term debt. As of
March 26, 2005, the unpaid fixed rent was $928,000 of which $831,000 is current.

The primary cash requirements of the Company are for maintaining current
operations, debt service and capital expenditures to grow the network of
Associated Centers and Company-managed Centers. In particular, spending on
employee salaries, advertising, cost of goods, advertising and rents is required
to operate the business.

Sources of Cash, Liquidity and Capital Resources

In the 13 weeks ended March 26, 2005, net cash used in operations was $3.0
million.

Net cash used in financing activities was $926,000 for the 13 weeks ended March
26, 2005, compared to net cash provided of $4.1 million for the same period in
2004. During the 13 weeks ended March 26, 2005, the Company paid principal on
capital leases of $1.0 million.

Capital expenditures were $1.0 million for the 13 weeks ended March 26, 2005,
compared to $465,000 for the same period in 2004. The capital expenditures in
the 13 weeks ended March 26, 2005 were primarily related to the buildout of new
Centers and the purchase of new LATW devices.

While the Company does not invest in derivative financial instruments or deal in
interest rate swaps, it does have debt obligations that are sensitive to changes
in interest rates and that have derivative instruments associated with them.



                                       16


Inflation

In general, the Company does not believe that inflation has had a material
effect on its results of operations in recent years. However, there can be no
assurance that the Company's business will not be affected by inflation in the
future.

Seasonality

The Company believes that its business follows seasonal trends due to increased
consumer demand during the spring and around public and national holidays. As a
result, the Company's sales performance could potentially be affected.


ITEM 3.           QUALITATIVE AND QUANTITATIVE DISCLOSURE ABOUT MARKET RISK

We believe there has been no material change in our exposure to Market Risk from
that discussed in the Company's Annual Report on Form 10-K for the fiscal year
ended December 25, 2004.


ITEM 4.           CONTROLS AND PROCEDURES

Company management is aware of certain deficiencies in the design or operation
of the Company's disclosure controls and internal accounting controls.

In connection with its audit of the Company's 2004 financial statements,
Deloitte & Touche LLP reported that (1) inadequacies in the design and execution
of the Company's internal control structure, and (2) improper application of
accounting principles in accordance with GAAP, constitute material weaknesses in
the Company's internal control structure for the year ended December 25, 2004.
The inadequacies in the Company's control structure included deficiencies or
inadequacies in the following specific areas: payments made to vendors without
adequate supporting documents, communication of all transactions to the
financial department, segregation of duties among finance department employees,
recording of inventory and physical inventory counts, tracking of fixed assets,
and timely completion of account reconciliations. Although any one of the
foregoing categories may not relate to material dollar amounts, in the aggregate
they represent a material weakness in the Company's internal control structure.
With respect to any specific adjustments identified in the audit process related
to improper application of accounting principles or inadequacy of internal
controls, the Company believes that all such adjustments have been made.

The Company's management, with the participation of its Chief Executive Officer
and Chief Financial Officer, have evaluated the effectiveness of the Company's
"disclosure controls and procedures" (as defined in Exchange Act Rule 13a-15(e))
as of the end of the period covered by this report. During the course of the
evaluation, the additional procedures performed and controls instituted by the
Company to enhance its internal controls and mitigate the effect of deficiencies
and to prevent misstatements or omissions in its consolidated financial
statements were considered. Based on this evaluation, the Company's Chief
Executive Officer and Chief Financial Officer concluded that as a result of the
material weaknesses referred to above, the Company's disclosure controls and
procedures are not fully effective as of the end of the period covered by this
report.

The Company has made, and will continue to make, improvements to its policies,
procedures, systems and staff who have significant roles in disclosure controls
and in internal controls over financial reporting, to address the identified
deficiencies. In addition, management has begun its project to comply with the
requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Management
anticipates that this effort will also help to more formally document,
communicate, and comply with the Company's accounting policies and procedures,
as well as to identify and rectify any residual disclosure or reporting
process control issues that may exist but, at this time, are unknown to
management.




                                       17



                                    PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

The Company is the subject of certain legal actions. Management does not believe
that current pending litigation involving the Company will have a material
adverse effect on the Company's consolidated financial position or results of
operations. This conclusion has been developed in consultation with outside
counsel handling BriteSmile's defense in the matters. However, the litigation
and other claims noted in this report are subject to inherent uncertainties and
it is possible that future results of operations for any particular quarterly or
annual period could be materially affected by changes in management's
assumptions and the effectiveness of BriteSmile's strategies related to these
legal actions.

BriteSmile, Inc. v. Discus Dental, Inc. and Salim Nathoo, filed in the United
States District Court for the Northern District of California (the "Discus
Patent Litigation"). The Company filed an initial complaint against Discus
Dental, Inc. ("Discus"), Culver City, California, in July 2002. As amended to
date, the complaint asserts claims of infringement of the Company's U.S. Patents
Nos. 6,343,933, 6,514,543 and 6,536,628. In February 2003, the Company amended
the Discus Patent Litigation by adding Salim Nathoo ("Nathoo") as a defendant.
The complaint, as amended, further alleges misappropriation of the Company's
trade secrets, civil conspiracy, and unfair competition and business practices
by Discus and Nathoo; breach of contract and breach of fiduciary duty by Mr.
Nathoo, and tortuous interference with contract by Discus. The complaint alleges
that Nathoo and Discus conspired to misappropriate BriteSmile's trade secrets in
violation of Nathoo's contractual obligations to the Company. The amended
lawsuit alleges that, as BriteSmile's Medical Director, Nathoo had, and
continues to have, an obligation to keep BriteSmile's trade secrets
confidential. Beginning in 2001, Discus Dental and Nathoo entered into an
agreement whereby Discus Dental paid Nathoo at least $2.5 million over a less
than two year period for Nathoo's "consulting" services, which included paying
Nathoo to share with Discus certain of the Company's trade secrets. The lawsuit
alleges further that in December 2002, a third party informed BriteSmile of
Nathoo's activities, and that when confronted by BriteSmile, Nathoo admitted to
receiving $2.5 million from Discus. The Company seeks a permanent injunction
against both Discus and Nathoo to prevent further infringement of its patents
and improper disclosure of the Company's trade secrets, lost profits, treble
damages and attorneys fees for willful patent infringement, punitive damages,
and other relief.

In March 2003, Discus filed its answer to the amended complaint and
counterclaims. In its answer, Discus denies any liability for BriteSmile's
claims. Discus also raises affirmative defenses, including claims that its
products and processes do not infringe BriteSmile's patents and that
BriteSmile's patents are invalid and unenforceable. Discus asserts counterclaims
against BriteSmile, seeking (i) judicial declarations that BriteSmile's patents
are invalid, unenforceable, and have not been infringed, (ii) tortuous
interference with prospective economic advantage and economic business
relations, and (iii) unfair competition. Discus also asks for declarations that
its products and processes do not violate BriteSmile's patents, that
BriteSmile's patents are unenforceable, that BriteSmile has no protectable trade
secrets, and that BriteSmile's contracts with Associated Center dentists which
contain contractual restrictions on the purchase and use of competitive systems
are unenforceable and should be enjoined, and is seeking lost profits, treble
damages and attorneys fees.

In July 2003, the case of Salim Nathoo v. BriteSmile Leasing (discussed below)
was consolidated with the Discus Patent Litigation.

In April 2004, Nathoo filed an answer and counterclaim to the Company's
complaint, as well as a third party complaint against Montgomery, who is a
director of the Company, and several of Montgomery's companies, alleging breach
of contract, breach of covenant of good faith and fair dealing, trade secret
misappropriation, patent infringement, and civil conspiracy. In August 2004,
Nathoo filed an amended answer and counterclaims to the Company's complaint. In
his new amended counterclaims, Nathoo brought claims for correction of
inventorship of several of the Company's patents; infringement by the Company of
those same patents; misappropriation of trade secrets by the Company, Montgomery
and several of his companies, and the following Company employees or directors:
John Reed, John Warner and Anthony Pilaro; conversion by the Company, Montgomery
and his companies, Reed, Warner and Pilaro; constructive trust for the patents
he claims have incorrect inventorship; fraud against the Company, Montgomery,
Reed, Warner and Pilaro; breach of contract by the Company, Montgomery, Reed,
Warner, Pilaro and CAP Advisors Limited; tortious interference with contract by


                                       18


the Company; a declaration that the Company has no protectable trade secrets;
and unfair competition against the Company, Montgomery and his companies, Reed,
Warner and Pilaro. In October 2004, Nathoo filed another amended answer and
counterclaims in which he dropped his allegations of patent infringement.

In May 2005, the Court dismissed with prejudice seven of Nathoo's counterclaims
pertaining to correction of inventorship as well as the counterclaim against CAP
Advisors for breach of contract.  The Court issued the claims construction order
construing the five claims in dispute in May 2005, and the parties have been
asked to submit a case schedule.  Further written discovery, document
production and depositions will continue.

Smile Inc. Asia Pte. Ltd. v. BriteSmile In April 2002, Smile Inc. Asia Pte. Ltd.
("Smile") sued the Company and BriteSmile Management, Inc., a wholly owned
subsidiary of the Company ("BriteSmile Management"), in the Third Judicial
District Court in Salt Lake City, Utah. The complaint alleges that BriteSmile
Management breached its 1998 distributor agreement with Smile (exclusive as to
Singapore and other surrounding countries) by failing to fill orders placed and
to perform other obligations under the agreement. The complaint also alleges
that BriteSmile Management and the Company fraudulently induced Smile to enter
into the distributor agreement, and includes claims for damages based on alleged
unjust enrichment, civil conspiracy, breach of the duty of good faith and fair
dealing, interference with contractual and economic relations, and fraudulent
transfer.

In May 2002, the Company and BriteSmile Management filed their answer and
counterclaim. The counterclaim alleges that Smile breached the distributor
agreement by, among other things, failing to operate using a licensed dentist in
good standing (the license of the principal of Smile, Dr. Tan, was not
maintained in good standing during 1999) and using BriteSmile's names and marks
in a fashion not permitted by the distributor agreement.

One of the principal defenses to Smile's claims is that the distributor
agreement expressly excludes "non-laser-aided teeth whitening products and
processes" sold by the Company. Accordingly, in the lawsuit the Company asserts
the distributorship agreement does not grant Smile any rights to market and sell
the Company's current light activated teeth whitening ("LATW") or retail
products and Smile cannot claim damages for BriteSmile's marketing of such
products in the exclusive territory described in the distributor agreement.

In May 2004, the Company filed a motion to compel Smile to participate in
mandatory binding arbitration and to stay the litigation pending arbitration. In
June 2004, the Court denied the Company's motion to compel arbitration. On July
16, 2004, the Company filed a Notice of Appeal on the issue of compelling this
case to be decided by mandatory binding arbitration. The case is stayed at the
trial level until the appellate court decides whether to compel Smile to
participate in arbitration.

Both parties have produced documents and written responses in support of their
claims and defenses, and depositions of certain key witnesses have been taken
and are continuing. However, the Company is still waiting to receive from Smile
documents and evidence to support Smile's calculation of damages.

While the plaintiff has claimed $10 million in damages, management believes that
the likelihood of material damages to the Company is remote.

BriteSmile v. Discus Dental, Inc., filed in Contra Costa County Superior Court,
California. In May 2002, the Company filed a complaint against Discus Dental,
Inc. in Contra Costa County Superior Court, California, alleging causes of
action for intentional interference with contractual relationship, negligent
interference with contractual relationship, violation of Unfair Business
Practice Act - Loss Leader, violation of Unfair Business Practice Act, trade
libel and injunctive relief. The complaint alleges that Discus Dental and other
defendants yet to be identified wrongfully interfered with the Company's
contractual relationships with its Associated Center Dentists, in part by
writing letters with the purpose of inducing certain of the Company's Associated
Dentists to terminate their contracts with the Company and switch to Discus'
Zoom! system, and by making false and disparaging statements concerning the
Company's teeth whitening system. The Complaint seeks damages for loss of
business, punitive damages, injunctive relief, and costs of suit. This case was
stayed in March 2003 pending the resolution of the Discus Patent Litigation.

Kalow & Springut v. BriteSmile et. al., filed in the Supreme Court of the State
of New York, County of New York. In April 2003, the law firm of Kalow & Springut
("KS") filed a complaint against the Company, BriteSmile International, a


                                       19


subsidiary of the Company, and Anthony Pilaro, the Company's non-executive
Chairman. KS sought to recover alleged unpaid legal fees and expenses in the
amount of $768,000. Plaintiff also alleged that it was fraudulently induced to
incur the legal fees and expenses and sought to recover punitive damages of at
least $5 million.

On June 13, 2003, BriteSmile answered the Complaint and asserted counterclaims
against KS for negligence, malpractice and breach of contract.

On February 14, 2005, the parties settled the case, whereby BriteSmile has
agreed to pay $650,000 to Kalow & Springut in full and final settlement.

The Procter & Gamble Company v. Oraceutical LLC, IDEX Dental Sciences, Inc.,
Robert Eric Montgomery, BriteSmile, Inc. and BriteSmile Development, Inc., filed
in the United States District Court for the Southern District of Ohio. In June
2003, The Proctor & Gamble Company ("P&G") filed a complaint against the
defendants listed above alleging that Oraceutical LLC, IDEX Dental Sciences,
Inc. and Robert Eric Montgomery (collectively, the "REM Group") had breached an
agreement between the REM Group and P&G (the "Standstill Agreement") by entering
into a binding memorandum of understanding (the "MOU") with the Company and
BriteSmile Development, Inc. on May 9, 2003. Montgomery is a director of the
Company. Oraceutical LLC, which is owned by Montgomery, is a consultant to the
Company. The complaint also seeks a declaratory judgment that U.S. Patent Nos.
5,922,307, 6,331,292 and 6,488,914 (owned by the REM Group at the time the
complaint was filed) (the "Patents") are invalid and unenforceable, and that
P&G's Whitestrips product does not infringe the Patents. In its complaint P&G
asserts that the REM Group was obligated under the Standstill Agreement not to
take any action that would prevent it from granting rights to P&G under the
Patents sufficient at least for P&G's current Whitestrips products. P&G further
alleges that the REM Group breached that obligation by entering into the MOU
and, accordingly, P&G terminated the Standstill Agreement. P&G is seeking
monetary damages of at least $75,000 from the Company under the claims set forth
in its complaint. Defendants have filed a motion to dismiss P&G's declaratory
judgment action for non-infringement and invalidity as well as for breach of the
Standstill Agreement.

In February 2004,  the defendants  filed an answer,  affirmative  defenses,  and
counterclaims.  Affirmative defenses include anticipatory breach, unclean hands,
equitable estoppel, lack of justifiable controversy,  and lack of jurisdictional
amount. The counterclaims  asserted that P&G literally infringed U.S. Patent No.
6,488,914 by among other things,  making,  using, selling or offering to sell in
the United States the Crest Whitestrips.  The counterclaims  further allege that
P&G actively induced  infringement of the patents in suit by providing marketing
assistance  for,  advertising  and  otherwise  promoting  the Crest  Whitestrips
products to others for resale. The claims construction hearing occurred in April
2005 regarding the interpretation of the patent claims, and the ruling from this
hearing is still  pending.  There are currently no new motions  pending with the
Court other than the motion to dismiss filed by the Company at the outset of the
case, and a motion to compel discovery filed by P&G.

The Company is also subject to legal proceedings and claims in the ordinary
course of business, including claims of alleged infringement of trademarks and
other intellectual property rights. The Company is not aware of any such legal
proceedings or claims that it believes will have, individually or in the
aggregate, a material adverse effect on its business, consolidated financial
position, results of operations or liquidity.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the 13 week period ended March 26, 2005, the Company granted to key
employees and directors under its 1997 Stock Option and Incentive Plan
non-qualified options to purchase an aggregate of 852,443 shares of the
Company's common stock, at exercise prices ranging from $4.35 to $6.30 per
share. Options generally vest over a two to five-year period and have a maximum
term of ten years.

For all option grants, the Company claimed exemption from registration under the
Securities Act of 1933 in that the Company believes such grants were not "sales"
within the meaning of the Act. Shares issuable upon exercise of the options have
been or will be registered with the SEC pursuant to Registration Statements on
Form S-8.

On January 9, 2005, 240,000 shares of restricted stock were granted to the new
Chief Executive Officer upon his hire. The shares vest one-third upon grant and
one-third each of the two anniversary dates thereafter.



                                       20


ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None.

ITEM 5.  OTHER INFORMATION.

On May 16, 2005, BriteSmile, Inc. issued a press release announcing updated
financial results for the thirteen weeks ended March 26, 2005. A copy of the
updated press release is furnished herewith as Exhibit 99 to this Report and is
incorporated herein by reference. The company will also post this document on
its corporate website, www.britesmile.com, under the "company" link.
 
The information in Item 5 of Part II of this report is being furnished and shall
not be deemed "filed" for the purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section. The information in this Item 5 shall not be incorporated by
reference into any registration statement or other document pursuant to the
Securities Act of 1933, as amended. The furnishing of the information in this
Item 5 is not intended to, and does not, constitute a representation that such
furnishing is required by Regulation FD or that the information this Item 5
contains is material investor information that is not otherwise publicly
available.


ITEM 6.  EXHIBITS.


       31.1    Certification of Chief Executive  Officer pursuant to Section 302
               of the Sarbanes-Oxley Act of 2002 (filed herewith).

       31.2    Certification of Chief Financial  Officer pursuant to Section 302
               of the Sarbanes-Oxley Act of 2002 (filed herewith).

       32.1    Certification of Chief Executive  Officer pursuant to Section 906
               of the Sarbanes-Oxley Act of 2002 (filed herewith).

       32.2    Certification of Chief Financial  Officer pursuant to Section 906
               of the Sarbanes-Oxley Act of 2002 (filed herewith).

       99      Updated EarningsPress Release dated May 16, 2005 (filed herewith)


                                       21




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

BRITESMILE, INC.


/s/ Gregg Coccari                                    May 16, 2005
Gregg Coccari                                        Date
Chief Executive Officer
(Principal Executive Officer)



/s/ Ken Czaja                                        May 16, 2005
Ken Czaja                                            Date
EVP, Chief Financial Officer
(Principal Financial and Accounting Officer)


                                       22